Molecular Formula | C22H28O3 |
Molar Mass | 340.46 |
Density | 1.1236 (rough estimate) |
Melting Point | 158-1600C |
Boling Point | 416.25°C (rough estimate) |
Specific Rotation(α) | D +24.5° (chloroform) |
Flash Point | 237.6°C |
Water Solubility | 272.4ug/L(25 ºC) |
Solubility | DMSO: soluble20mg/mL, clear |
Vapor Presure | 8.95E-12mmHg at 25°C |
Appearance | powder |
Color | white to beige |
Storage Condition | room temp |
Refractive Index | 1.5000 (estimate) |
Physical and Chemical Properties | Slightly yellow or milky white crystalline powder (ethyl acetate). Melting point 149-151 ℃, curing and remelting at 165 ℃. |
Use | For the treatment of edema in heart failure and cirrhotic ascites |
In vitro study | Canrenone inhibits the production of eortieosterone, 18-hydroxydesoxyeortieosterone, 18-hydroxycorticosterone and aldosterone in a dose-dependent manner. Canrenone dose-dependently reduces platelet-derived growth factor–induced cell proliferation and motility. Canrenone inhibits the activity of the Na + /H + exchanger 1 induced by platelet-derived growth factor. |
In vivo study | Canrenone is the principal active metabolite of Spironolactone in the rat only for a limited period. During chronic treatment a difference developed between the effect of Spironolactone and Canrenone on the RAAS indicating a decrease in the anti-mineralocorticoid activity of Canrenone and an increase in the efficacy of Spironolactone. |
Risk Codes | R40 - Limited evidence of a carcinogenic effect R51/53 - Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. |
Safety Description | S36/37 - Wear suitable protective clothing and gloves. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. |
UN IDs | UN 3077 9 / PGIII |
WGK Germany | 3 |
HS Code | 29329990 |
LogP | 2.54 at 25℃ |
NIST chemical information | information provided by: webbook.nist.gov (external link) |
biological activity | Canrenone (Aldadiene; SC9376; SC14266) is an aldosterone antagonist widely used as a diuretic. |
Use | an intermediate of spironolactone. Itself is an aldosterone antagonist. canranone (spironolactone EP impurity F) is an aldosterone antagonist. Diuretics. For the treatment of edema of heart failure and cirrhosis of the liver ascites. |
production method | 17-hydroxy-3-oxo-17 α-pregnenol-4-ene-21-carboxylic acid-γ-lactone can be used prepared by dehydrogenation. While the former can be from 17 alpha-alkynyl-3 beta, 17 beta-dihydroxyandrosten-5-ene (I. E., acetylene androstenene diol) by alkynyl with methyl magnesium iodide replacement, hydrolysis, salt formation and catalytic hydrogenation to produce 3 beta, 17 beta dihydroxyandrostin-5-en-17 alpha-propionate potassium, and then the product is prepared by internal esterification and oxidation of the 3-position hydroxyl group. |